Ascletis Pharma (HKG:1672) said ASC47 the results for its new weight-loss drug, in combination with semaglutide, according to a Wednesday filing with the Hong Kong bourse.
In preclinical trials, the combination led to a 36.2% reduction in body weight in obese mice, outperforming semaglutide alone with muscle mass preserved.
The company plans further studies, with Phase II A results expected in 2025, aiming to advance obesity treatment options.
The pharmaceuticals shares were down by over 13% at day end.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.